---
title: "Nuvation Bio posts corporate deck highlighting IBTROZI ROS1+ NSCLC launch, safusidenib IDH1 glioma program"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293212909.md"
description: "Nuvation Bio highlighted IBTROZI (taletrectinib) as a key commercial driver, reporting USD 43 million in U.S. net product revenue as of March 2026 for advanced ROS1+ NSCLC. The company maintains a pro forma cash balance of approximately USD 736 million, sufficient to reach profitability without additional funding. Additionally, safusidenib is advancing in IDH1-mutant glioma via the SIGMA study, while its drug-drug conjugate platform remains preclinical."
datetime: "2026-07-20T12:18:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293212909.md)
  - [en](https://longbridge.com/en/news/293212909.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293212909.md)
generator: "portal-rs"
---

# Nuvation Bio posts corporate deck highlighting IBTROZI ROS1+ NSCLC launch, safusidenib IDH1 glioma program

-   Nuvation Bio highlighted IBTROZI (taletrectinib) as a commercial driver, with U.S. net product revenue of USD 43 million as of March 31, 2026. \* IBTROZI is marketed for advanced ROS1+ NSCLC in the U.S., Japan, China; EMA validated its marketing authorisation application. \* Pro forma cash balance pegged at about USD 736 million, positioned as sufficient to reach profitability without additional funding. \* Safusidenib positioned as a brain-penetrant IDH1 inhibitor, with a pivotal SIGMA study enrolling in IDH1-mutant glioma. \* Drug-Drug Conjugate platform remains preclinical, with candidates designed to bind two targets simultaneously. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief on July 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [NUVB.US](https://longbridge.com/en/quote/NUVB.US.md)
- [NUVB+.US](https://longbridge.com/en/quote/NUVB+.US.md)

## Related News & Research

- [Nuvation Bio wins FDA fast-track status for safusidenib in IDH1-mutant glioma](https://longbridge.com/en/news/296487028.md)
- [Nuvation Bio posts corporate presentation highlighting IBTROZI ROS1 lung cancer franchise](https://longbridge.com/en/news/295106076.md)
- [Nuvation Bio Q2 revenue beats estimates on IBTROZI growth](https://longbridge.com/en/news/295102967.md)
- [Nuvation Bio to present subgroup analyses from TRUST-I, TRUST-II taletrectinib studies in ROS1+ NSCLC at WCLC 2026](https://longbridge.com/en/news/294821032.md)
- [Is Royalty Pharma (RPRX) Undervalued On Its $100 Million Zealand Pharma Royalty Deal?](https://longbridge.com/en/news/296647266.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**